KOLEK, Vitezslav, Ivona GRYGARKOVA, Leona KOUBKOVA, Jana SKŘIČKOVÁ, Lenka OSTRIZKOVA, Jirina SVECOVA and Dimka SIXTOVA. Adjuvant Chemotherapy in Patients with Resected Non-Small-Cell- Lung Cancer Treated with Carboplatin and Oral Vinorelbine - SWITCH I Study. In 16th World Conference on Lung Cancer. 2015. ISSN 1556-0864.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Adjuvant Chemotherapy in Patients with Resected Non-Small-Cell- Lung Cancer Treated with Carboplatin and Oral Vinorelbine - SWITCH I Study
Authors KOLEK, Vitezslav (203 Czech Republic), Ivona GRYGARKOVA (203 Czech Republic), Leona KOUBKOVA (203 Czech Republic), Jana SKŘIČKOVÁ (203 Czech Republic, guarantor, belonging to the institution), Lenka OSTRIZKOVA (203 Czech Republic), Jirina SVECOVA (203 Czech Republic) and Dimka SIXTOVA (203 Czech Republic).
Edition 16th World Conference on Lung Cancer, 2015.
Other information
Original language English
Type of outcome Conference abstract
Field of Study 30203 Respiratory systems
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 5.040
RIV identification code RIV/00216224:14110/15:00084853
Organization unit Faculty of Medicine
ISSN 1556-0864
Keywords in English non small cell lung cancer; adjuvant chemotherapy; vinorelbine; carboplatin
Tags EL OK
Changed by Changed by: Ing. Mgr. Věra Pospíšilíková, učo 9005. Changed: 24/11/2015 14:33.
Abstract
Background: Adjuvant cisplatinum-based chemotherapy is recommended in patients with stages IB (> 4 cm), IIA, IIB, and IIIA of non small-cell lung cancer (NSCLC) after radical resection. Vinorelbine with cisplatin are preferable drugs in this indication, but the side effects of this treatment were not negligible in big adjuvant trials. Carboplatin with vinorelbine given intravenously switched to orally were applied in a multicentre prospective study SWITCH I to give better comfort, higher tolerability and comparable effectivenes as standard adjuvant chemotherapy. The recruitment period started in January 12th, 2005 and lasted till September 5th, 2008. Conclusion: Adjuvant chemotherapy with carboplatinum and vinorelbine given intravenously on the day 1 and orally on the day 8 in 21 day regimen appears to be a comfortable and tolerable therapy in radically resected NSCLC. It provides higher dose intensity and more of acomplished treatments compared to big adjuvant trials and LACE meta-analysis, in which these parametres varied between 50 % to 76 % only. Survival results are comparable to LACE (3-year survival 70,3% vs 64.3%), 5-year survival 56,2% vs 55.1%) and MOS 5.9 vs 5.15 y).
PrintDisplayed: 27/7/2024 13:47